Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBG004
- Development stage
- Unknown
- Lead developer
- Sonoran Biosciences
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Local Infiltration, Peri-neural
01
Overview
SBG004 is an extended-release formulation of bupivacaine designed for the treatment of postoperative pain. It utilizes a proprietary temperature-responsive polymer (poly(N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M-1000 acrylamide), abbreviated as PNDJ) to form a gel at body temperature, creating a depot that releases bupivacaine locally over several days. This approach aims to provide effective analgesia for 3–5 days or longer, potentially reducing or eliminating the need for opioids after surgery. Preclinical studies have demonstrated that SBG004 can provide analgesia lasting up to 120 hours in animal models and may outperform current local anesthetic options in both duration and efficacy[1][2][5][7].
- Other names
- bupivacaine extended-release gel-forming solution
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on SBG004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBG004.